(Q34056907)

30 July 2017

1 reference

title

Clinical use of topoisomerase I inhibitors in anticancer treatment (English)

1 reference

30 July 2017

C Rodriguez-Galindo

1

1 reference

30 July 2017

K Radomski

2

1 reference

30 July 2017

C F Stewart

3

1 reference

30 July 2017

W Furman

4

1 reference

30 July 2017

V M Santana

5

1 reference

30 July 2017

P J Houghton

6

1 reference

30 July 2017

1 October 2000

1 reference

30 July 2017

Pediatric Blood Cancer

1 reference

30 July 2017

35

1 reference

30 July 2017

385-402

1 reference

30 July 2017

4

1 reference

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

Current perspectives on camptothecins in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001001%2935%3A4%3C385%3A%3AAID-MPO1%3E3.0.CO%3B2-E

10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference